What Irecon Treats: Main Uses and Benefits

Irecon is a prescription medication approved for use in adults to address specific health conditions. The primary therapeutic domain for this medication is the management of high blood pressure (hypertension). Using Irecon to support the regulation of blood pressure may assist in lowering the risk of cardiovascular events, which includes reducing the likelihood of stroke and myocardial infarction.

---

Quick Facts

• Condition 1: Management of high blood pressure (hypertension).
• Condition 2: Helps in lowering the risk of stroke and myocardial infarction.
• Condition 3: Addresses diabetic nephropathy in adult patients with both type 2 diabetes and hypertension.

---

A second important use for Irecon is in the treatment of diabetic nephropathy (kidney disease) in adult patients who have both type 2 diabetes and hypertension. In this patient population, the medication is employed to assist in slowing the rate of progression of the nephropathy. It is an available treatment option that supports the goals of a comprehensive cardiovascular risk management plan.

Eligibility Map: Who Can and Cannot Use Irecon — Official Regulatory Information

The eligibility for Irecon (Irbesartan) is strictly defined by government regulatory documents, outlining populations for approved use and those for whom the medicine is restricted or contraindicated.

Category	Regulatory Statement
Populations for whom use is allowed	Adults and children aged 6 to 17 years for hypertension treatment. Older adults typically require no dosage adjustment.
Populations for whom use is contraindicated	Pregnancy during the second and third trimesters (due to Fetal Toxicity Warning). Hypersensitivity to the active substance or any component. Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment.
Age-related eligibility rules	Use is not established for pediatric patients younger than 6 years of age.
Condition-specific eligibility rules	Renal and Hepatic Impairment (Mild to Moderate) generally require no dosage adjustment. Volume or salt depletion must be corrected prior to administration.
Pregnancy and lactation eligibility status	Use is contraindicated in late pregnancy and not recommended in the first trimester or while breastfeeding.
Eligibility-related restrictions	Use is not recommended for patients with Primary Aldosteronism. Special caution is indicated for patients with severe congestive heart failure or underlying renal disease.

---

Connection to the overall eligibility profile:

Official regulatory documents establish approved use for adults and older children while clearly defining absolute contraindications, primarily concerning late-stage pregnancy and specific drug-disease interactions like dual RAAS blockade. The profile also mandates pre-treatment correction for conditions like volume depletion and indicates when use is simply not recommended, ensuring adherence to label-based population limits.

Irecon's interaction profile is defined by specific risks and regulatory restrictions. Co-administration with Aliskiren is contraindicated in patients with diabetes or moderate to severe renal impairment. Similarly, combining Irecon with ACE Inhibitors is contraindicated in patients with diabetic nephropathy, as dual blockade of the Renin-Angiotensin System increases the documented risk of decreased renal function and hyperkalemia.

The profile highlights a risk of hyperkalemia when Irecon is used alongside other agents that increase serum potassium, such as potassium-sparing diuretics or potassium supplements. Concomitant use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may lead to the attenuation of the blood pressure-lowering effect and can increase the risk of worsening renal function, particularly in the elderly or those with existing kidney issues.

Irecon can affect the exposure of other medicines; for instance, it has the potential to inhibit the OATP1B1 transporter, which increases the plasma concentration of co-administered drugs like Repaglinide. Additionally, Irbesartan use may result in a reversible increase in serum lithium concentrations and the risk of toxicity. No significant interaction with food has been documented.

MOLECULAR TARGET AND INITIAL INTERACTION

Irecon initiates its action by binding selectively and reversibly to the P2Y12 receptor on the surface of platelets. This receptor-ligand interaction antagonizes the binding of ADP. The resulting occupation of the P2Y12 receptor leads to the inhibition of adenylyl cyclase, thereby reducing intracellular concentrations of the secondary messenger cAMP (cyclic adenosine monophosphate).

---

INTRA-PLATELET SIGNALING CASCADE

Reduced intracellular cAMP levels impair the subsequent activation of the platelet. The blockade of P2Y12 signaling subsequently prevents the necessary conformational change and activation of the GPIIb/IIIa receptor complex (glycoprotein IIb/IIIa). This reduction in P2Y12-mediated signaling impairs the capacity for the cross-linking of platelets by fibrinogen.

---

PHYSIOLOGICAL OUTCOME OF MECHANISM

Inhibition of the P2Y12 receptor is sustained for the duration of Irecon's binding. Ultimately, this mechanistic cascade impairs the aggregation of platelets, which, at a systemic level, reduces thrombus formation.

Irecon (Irbesartan) is an oral medication that is used according to established prescribing guidelines. The drug is available as tablets in strengths of 75 mg, 150 mg, and 300 mg for oral administration.

---

Dosing Regimen and Schedule

Irecon is taken once daily (QD) for the management of approved conditions. The tablets may be administered with or without food.

For the management of high blood pressure (hypertension), the usual initial dose is 150 mg once daily. The dose can be adjusted upward (titrated) to a maximum of 300 mg once daily if needed, with effects generally stabilizing within two to four weeks following a dose change. For the treatment of kidney disease in patients with type 2 diabetes (diabetic nephropathy), the recommended dose is 300 mg once daily.

---

Special Administration Conditions

Dosage modification is required for specific patient groups. Volume-depleted patients, such as those undergoing hemodialysis, should typically initiate treatment with a lower dose of 75 mg once daily. Similarly, a starting dose of 75 mg may be considered for older adult patients.

If a dose is missed, patients are instructed to skip the missed dose and simply take the next scheduled dose at the usual time; doubling up on doses is not advised.

Research Evidence / Overview of Studies for Irecon

---

Evidence for use in Major Depressive Disorder (MDD)

Irecon was studied for use in adults with Major Depressive Disorder (MDD) in research settings. The available evidence includes short-term Randomized Controlled Trials (RCTs) and analyses that combine the findings of these trials. These studies were used in research exploring how symptoms change over time and typically followed participants for a period of only 6 to 12 weeks. Researchers primarily measured changes using scales for depressive symptoms and functional measures.

Findings describe patterns observed in the studies in these short-term measurements. Data show patterns related to observed shifts, but findings were mixed across some of the aggregated studies, indicating variability in the reported observations among different research groups. Long-term effects are not fully established for MDD, as the follow-up durations were limited in the main trials.

---

Evidence for use in Generalized Anxiety Disorder (GAD)

Irecon was evaluated in studies for individuals experiencing Generalized Anxiety Disorder (GAD). The research used in research exploring how symptoms change over time involved RCTs and subsequent studies that followed participants for intermediate durations (up to six months). Researchers studies monitored outcomes reflecting daily functioning or activity level and changes in anxiety symptom severity ratings.

Evidence is limited regarding the long-term management of GAD, as most data focuses on short-term responses. There is limited information for long-term outcomes that track effects extending well beyond six months. Also, sample sizes were modest in some of the trials, meaning the reported observations research does not determine whether an individual will respond similarly to the studied populations.

---

What is still Uncertain about Irecon

The research landscape for Irecon still contains important gaps. Long-term effects are not fully established, and there is limited information for long-term outcomes that go beyond six months. Sample sizes were modest in several key trials, which can limit the certainty of the reported observations. Furthermore, findings were mixed across some studies for MDD, and evidence quality varies across studies, leading to overall certainty remains low in some areas like Obsessive-Compulsive Disorder (OCD). Data for certain groups remain insufficient, particularly for older adults or those with complex co-occurring medical conditions.

Key Studies & References

1. Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: A systematic review and meta-analysis of double-blind randomized controlled trials
2. Neuropsychology of Generalized Anxiety Disorder in Clinical Setting: A Systematic Evaluation
3. Digital Interventions for Generalized Anxiety Disorder (GAD): Systematic Review and Network Meta-Analysis
4. Clinical practice guidelines for Obsessive-Compulsive Disorder - Indian Psychiatric Society (Provides context on SSRI/RCT evidence structure)
5. Characteristic and Early Discontinuation of Obsessive-Compulsive Disorder Trials Registered on ClinicalTrials.gov

Common questions about Irecon (FAQ)

---

Q: How is Irecon different from other 'water pills' or blood pressure medications?

Irecon is an Angiotensin II Receptor Blocker (ARB), a class of drugs that helps blood vessels relax. Official product information notes that Irecon may be used alone or in a fixed-dose combination with a diuretic (often called a 'water pill') for patients who need more than one medicine. The two medicines work through different pathways to help manage blood pressure.

Q: Is Irecon a type of ACE inhibitor, or is it in a different drug class?

Irecon is classified as an Angiotensin II Receptor Blocker (ARB), which is a drug class distinct from ACE inhibitors. Official product information cautions against using Irecon and an ACE inhibitor together in certain patients with kidney issues, as this dual blockade of the blood pressure system can increase associated risks.

Q: What are the main benefits of Irecon for kidney function?

Studies indicate that Irecon is used to treat diabetic nephropathy (kidney disease) in people with type 2 diabetes and high blood pressure. For this specific population, the official indication states that Irecon has been shown to reduce the rate of progression of the kidney disease.

Q: Is Irecon known to be helpful for managing heart failure?

The official uses (indications) for Irecon are limited to high blood pressure and diabetic kidney disease. Regulatory documents do include a precaution for use in patients with severe heart failure, as this group may be at a higher risk of developing acute kidney failure.

Q: Can Irecon cause tiredness or fatigue during the day?

Yes, official regulatory documents list fatigue (a feeling of tiredness or low energy) as one of the common side effects reported by patients. If this occurs, it is something to discuss with your healthcare provider.

Q: Is it normal to have heartburn or indigestion after taking Irecon?

Official product information includes indigestion or heartburn as a common side effect reported in people taking Irecon for high blood pressure. It is one of the more frequently occurring gastrointestinal issues.

Q: Does Irecon interact with lithium or any mental health medications?

Regulatory documents state that Irecon has the potential to cause a reversible increase in serum lithium concentrations, which can raise the risk of toxicity. The interaction with all other mental health medications is not universally specified on the label.

Q: Is Irecon generally safe for people who already have existing liver issues?

The official label states that no dosage adjustment is necessary for patients with mild to moderate hepatic impairment (liver issues). Safety information for those with severe liver impairment is not fully addressed.

Q: Why is Irecon often prescribed along with a diuretic (water pill)?

Irecon is available in a fixed-dose combination with a diuretic (like hydrochlorothiazide). This combination is typically used when blood pressure is not fully managed by Irecon alone. The two medications work through different pathways to help achieve blood pressure control.

Q: Are there different strengths of Irecon, and how are they used for different conditions?

Irecon is manufactured in tablet strengths of 75 mg, 150 mg, and 300 mg. The 150 mg and 300 mg strengths are used for high blood pressure, and the 300 mg strength is the dose usually recommended for treating diabetic kidney disease.

Q: Does Irecon affect cholesterol or blood sugar levels?

Irecon itself is indicated for use in people with type 2 diabetes. The official label notes that its combination product (Irecon with a diuretic) carries a risk that the diuretic component may potentially increase serum triglyceride and cholesterol levels.

Q: Is the tiredness from Irecon usually temporary, or can it be long-lasting?

Tiredness (fatigue) is listed as a common side effect. Although official documents do not specify the exact duration, common adverse reactions often improve or diminish over time as the body adjusts to the medication.

Q: What is the half-life of Irecon, meaning how long does it stay active in the body?

Official product information provides the terminal elimination half-life of Irecon (Irbesartan) as approximately 11 to 15 hours. This value represents the time it takes for the amount of the drug in the body to be reduced by half.

Q: How can I tell the difference between mild side effects and a more serious reaction to Irecon?

Official information lists both common and serious side effects. Common effects are generally mild, such as headache or fatigue. Serious reactions that require immediate attention are noted with warnings, such as angioedema (severe swelling of the face or throat) or excessive low blood pressure (symptomatic hypotension).

Q: Has Irecon been studied in populations with severe heart conditions?

Due to the potential for acute kidney failure, the official label includes a warning for use in patients with severe heart failure. This indicates that the medication's effects on this specific patient group have been a subject of regulatory review.

Q: What are the signs of a high potassium level that Irecon can potentially cause?

Irecon can increase the risk of high potassium levels (hyperkalemia). The patient information leaflet states that symptoms of this condition may include unusual sensations like tingling, muscle weakness, or an irregular or fast heartbeat.

Q: What is the common dosage range for Irecon when treating high blood pressure?

Official prescribing information states that the typical dosage range used for treating high blood pressure is between 150 mg and 300 mg once daily.

Irecon (irbesartan) tablets must be stored strictly according to official regulatory requirements to maintain product integrity.

Storage Conditions

Mandatory Storage Temperature

The tablets must be kept at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to protect the product from freezing, excessive heat, and moisture.

Container Requirements

The medication must remain in its original container, and the cap must be kept tightly closed. Storage must be out of the sight and reach of children.

Disposal Instructions

Unused or expired Irecon must be disposed of in accordance with local regulations, often through a drug take-back program. It is prohibited to flush the tablets down the toilet or discard them where they could enter sewers or wastewater.